Key result
HFmrEF shows similar 5-year survival to HFpEF in post-MI patients.
Why the study?
The long-term prognostic effect of inflammatory biomarkers in patients with myocardial infarction and heart failure with preserved and mid-range ejection fraction was not well established.
Do inflammatory biomarkers predict 5-year mortality in patients with MI and HFmrEF or HFpEF?
Population
135 patients with MI and HFpEF or HFmrEF from a PCI registry in 2012-2013
Comparison
Patients with HFpEF versus HFmrEF and varying levels of inflammatory biomarkers
Design
Prospective cohort study with biomarker measurements at admission, 12 and 60 months
Follow-up
60 months
Authors
Loading...
HFmrEF and HFpEF warrant similar post-MI surveillance; hypothesis-generating for MMP-9 and homocysteine in mortality prediction.
Cohort (n=135)
Do inflammatory biomarkers predict 5-year mortality in patients with MI and HFmrEF or HFpEF?
Absolute Event Rate: 85% vs 89.1%
p-value: p=0.492
Elevated levels of MMP-9, homocysteine, and platelets are significant predictors of 5-year mortality in patients with MI and HFmrEF or HFpEF following PCI.
Musikhina et al. (2020) conducted a cohort in Myocardial infarction and heart failure with preserved and mid-range ejection fraction (n=135). Heart failure with mid-range ejection fraction (HFmrEF) vs. Heart failure with preserved ejection fraction (HFpEF) was evaluated on Survival at 60 months (p=0.492). Heart failure with mid-range ejection fraction had similar 60-month survival compared to preserved ejection fraction (85.0% vs 89.1%, p=0.492) in patients post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: